AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04212949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
Study NCT04212949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural steroid injection
Description: An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)
Study NCT04212949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural steroid injection
Description: An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)
Study NCT03262688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl collagen-matrix implant
Description: Placement of the bupivacaine collagen-matrix in the surgical site
Study NCT03262688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl infiltration
Description: Infiltration of the surgical site
Study NCT02048306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based PR program
Description: The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
Study NCT02048306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PR program
Description: The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
Study NCT00591643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging, Adrenal acans
Description: The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
Study NCT00591643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (NP-59)
Description: One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
Study NCT04504396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Study NCT04504396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Study NCT03101878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ionis AGT-LRx
Description: Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
Study NCT03101878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline .9%
Study NCT01351688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3514
Description: Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
Study NCT01770938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Effective light-emitting diode therapy
Study NCT01770938 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light-emitting diode therapy
Study NCT02853279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval exercise training
Description: Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week.
Study NCT02853279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise training (CON)
Description: Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
Study NCT01901666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: All GH deficient patients with bone age \<14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy
Study NCT00098826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study NCT00098826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00098826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00319358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants
Description: 600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
Study NCT00319358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03365726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dobutamine stress test with trans-esophageal echocardiography
Description: Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~* If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~* If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored.
Study NCT04133376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping with nicotine
Description: Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
Study NCT04133376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping without nicotine
Description: Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
Study NCT03970122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFB-887
Description: IMP
Study NCT03970122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching
Study NCT02185690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Binimetinib
Description: Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule.
Study NCT02185690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: 4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
Study NCT02185690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: 4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
Study NCT02347501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin (Januvia)
Description: Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
Study NCT00683202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Study NCT00683202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Study NCT00005576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody Ch14.18
Description: Given IV
Study NCT00005576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study NCT00005576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study NCT00005576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given IV
Study NCT02448927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon aortic valvuloplasty
Study NCT02448927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Implantation
Study NCT02448927 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcatheter Aortic Valve Implantation
Study NCT00041496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-207266
Description: White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
Study NCT00041496 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match SB-207266
Study NCT05067361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
Study NCT05067361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ball Exercises
Description: Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
Study NCT05067361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ball Exercises
Description: Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
Study NCT03087032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
Study NCT03087032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
Study NCT03772496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circulating tumor cells test
Description: 10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
Study NCT03772496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy
Description: patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
Study NCT02253797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Tipranavir
Study NCT02253797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02253797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT04010331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nokyong Mixture Extract(CME-PI)
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study NCT04010331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 week
Study NCT02899338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI695501 Prefilled syringe
Study NCT02899338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI695501Autoinjector
Study NCT00322257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study NCT00322257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose
Study NCT00322257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose
Study NCT00322257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c.
Study NCT03585530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: Raltitrexed 2.6mg/m2 was administered on d1、d22
Study NCT04351516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
Study NCT04351516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Film Coated Tablette
Study NCT04570904 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccination at different time points
Description: All HCWs will receive the seasonal influenza vaccine but at two different time points.
Study NCT01184196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Swab area with Betadine
Description: A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
Study NCT01184196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Swab area with ChloraPrep
Description: A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
Study NCT03133364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensory optimized meals
Description: 19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
Study NCT03133364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory optimized meals
Description: 19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
Study NCT02272777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 400mg QD，300mg QD or 600mg QD
Study NCT02272777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300mg BID or 400mg QD
Study NCT04529746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project
Description: Brief behavioral intervention (4 hours across two meetings)
Study NCT02804737 — intervention group
Intervention type: DEVICE
Intervention: Aiddly (Web Site)
Description: A website designed to better educate patients on how to prepare for their colonoscopies
Study NCT02992678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
Study NCT02992678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
Study NCT00006734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00006734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00006734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00006734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00006734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00006734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00006734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00006734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00006734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00006734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT00006734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02829970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUCCEEDS Program
Description: Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention \& Alcohol Disorders (BAAAD).
Study NCT02829970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living a Healthy College Lifestyle
Description: Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
Study NCT01658293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: thermal stimulation
Description: The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
Study NCT01658293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group ergometer exercises
Description: The control group will be given ergometer exercises with the similar duration as experimental group.
Study NCT00167505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Avoidance Intervention
Description: The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
Study NCT00167505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Intervention
Description: The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
Study NCT01174134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional beverage
Study NCT01174134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional beverage